Key clinical point: Psoriasis patients on apremilast may be more satisfied with their care compared with those on a biologic.
Major finding: The medication switch rate within 12 months was 14% in biologic-naive psoriasis patients who started on apremilast, similar at 11% in those placed on an interleukin inhibitor, and significantly higher at 25% in patients who started on a workhorse TNF inhibitor.
Study details: This was a retrospective analysis of claims data focused on medication switch rates among biologic-naive psoriasis patients who started on either apremilast, a TNF inhibitor, or an interleukin inhibitor.
Disclosures: The presenter reported serving as a consultant and paid speaker for Celgene, the study sponsor, as well as for several other pharmaceutical companies.
Kaplan DL. EADV Abstract FC04.04.